Inhibrx to webcast interim Phase 2 HexAgon results for INBRX-106 in HNSCC
PUBT · 05/08 20:10
Share
Listen to the news
- Inhibrx scheduled a May 11, 2026 webcast to present interim results from randomized Phase 2 HexAgon study of INBRX-106 combined with pembrolizumab versus pembrolizumab alone in first-line head and neck squamous cell carcinoma.
- Update will focus on early read on whether adding INBRX-106 improves clinical benefit while maintaining acceptable safety in treatment-naïve, PD-L1 positive patients with metastatic or unresectable recurrent disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved